This is a repository copy of Assessment of atrial fibrosis for the rhythm control of atrial fibrillation.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/105049/

Version: Accepted Version

Article:
Begg, GA orcid.org/0000-0001-5260-4293, Holden, AV, Lip, GYH et al. (2 more authors) (2016) Assessment of atrial fibrosis for the rhythm control of atrial fibrillation. International Journal of Cardiology, 220. pp. 155-161. ISSN 0167-5273

https://doi.org/10.1016/j.ijcard.2016.06.144

© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Assessment of Atrial Fibrosis for the
Rhythm Control of Atrial Fibrillation

Gordon A. Begg MBChB\textsuperscript{1,2} Arun V. Holden PhD\textsuperscript{2} Gregory Y. H. Lip MD\textsuperscript{3} Sven Plein MD PhD\textsuperscript{2} Muzahir H. Tayebjee MD\textsuperscript{1}

\textsuperscript{1}Leeds General Infirmary, UK
\textsuperscript{2}University of Leeds, UK
\textsuperscript{3}University of Birmingham, UK

Address for Correspondence:
Dr. Gordon Begg, Ward X39 Offices, Leeds General Infirmary, Great George St, Leeds, UK, LS1 3EX Email: gordon.begg@nhs.net Tel: +447969138882

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Dr. Begg declares research fellowship funding from St. Jude Medical, St. Paul, MN.

Prof. Lip has served as a consultant for Bayer, Astellas, Merck, Sanofi, Bristol-Myers Squibb/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo; and has been on the speakers bureau for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo. The other authors report no relationships that could be construed as a conflict of interest

Keywords: Atrial fibrillation, fibrosis, catheter ablation, cardioversion
Abstract

Rhythm control of atrial fibrillation (AF) remains challenging, with modest long term success rates. Atrial fibrosis has been associated with AF, but the clinical utility of assessment of this fibrosis has yet to be fully elucidated. In this paper we review the current state of understanding of the pathophysiology of atrial fibrosis in AF, and its impact upon the instigation and propagation of the arrhythmia. Fibrosis causes an increase in volume of dysfunctional extracellular matrix, and is associated with cellular alterations such as hypertrophy, apoptosis and membrane dysfunction within the atrial myocardium. In turn, these cause pathological alterations to atrial conduction, such as increased anisotropy, conduction block and re-entry, which can lead to AF. We review current methods of assessing atrial fibrosis and their impact upon the prediction of success of interventional rhythm control strategies such as ablation and cardioversion. We focus particularly on circulating biomarkers of fibrosis and scar formation; their role in the fibrotic process, and their value in the prediction of rhythm control success. We also review imaging and invasive electrocardiographic mapping techniques that may identify fibrosis, and again assess their potential predictive value. In this area there exist many unanswered questions, but further work will help to refine techniques to reliably identify and treat those patients who are most likely to benefit from rhythm control treatment strategies.
Introduction

Reliable prediction of treatment success for a rhythm control strategy for atrial fibrillation (AF) is highly desirable, to minimise unnecessary exposure to procedural risk and improve outcomes. Clinical factors favouring rhythm control strategies such as ablation include younger age, shorter duration of AF, paroxysmal AF, a structurally normal heart, and little comorbidity. Inflammatory disorders, valvular disease, left atrial dilatation, cardiomyopathy, and obesity are all considered clinical predictors of AF recurrence in individual trials, although a meta-analysis found no definitive clinical predictors of recurrent arrhythmia.[1]

Circulating biomarkers may serve as surrogate indicators for advanced atrial pathology that may reduce the likelihood achieving rhythm control. If such markers could be identified and used in conjunction with clinical and imaging criteria, patient selection could be improved, leading to improved success rates from rhythm control.

Left atrial fibrosis has been associated with AF, and shown to be a poor prognostic marker for maintenance of sinus rhythm. Circulating markers of fibrosis may therefore be used as markers of left atrial remodelling.

This review focuses on the pathophysiology of atrial fibrosis, the use of serological, electrophysiological, and imaging methods to identify this fibrosis,
and the ability of such methods to predict or improve the success of rhythm control treatment of AF.

**Selection criteria**

We searched *Medline* (up to November 2015) using the terms “atrial fibrillation” and “fibrosis”. The abstracts were screened and full articles relevant to the review were selected. In total, 87 articles were selected for inclusion.

**The extracellular matrix, collagen turnover, and fibrosis**

Cardiac extra-cellular matrix (ECM) consists predominantly of type I (80%) and type III collagen and plays an important role in maintaining tissue architecture. Furthermore, through interaction with fibroblasts and cardiomyocytes, involving TGF-β and angiotensin II paracrine signalling, the ECM has an important role in the detection of myocardial stretch. Normal ECM is also important for intercellular signalling as well as electrical conduction.

Procollagen is synthesised in the fibroblast endoplasmic reticulum and then converted to collagen in the extracellular space by cleavage of the amino and carboxyl terminal groups. The ECM is in a constant state of flux. A number of mechanisms regulate collagen turnover (*figure 1*), and involve transforming growth factor β (TGF-β), angiotensin II, platelet-derived growth factor, insulin-
like growth factor-1, growth hormone, and endothelins 1 and 3. Matrix metalloproteinases (MMPs) are primarily responsible for collagen degradation and IL-1, prostaglandin, tumour necrosis factor α (TNF-α), and brain natriuretic peptide (BNP) up regulate MMP production. Tissue inhibitors of MMPs (TIMPs) are the primary inhibitors of MMPs. MMPs 1, 2, 7, 8, 9, 10, and 13 have major roles in degrading type I and III collagen.

In AF, inflammatory changes in the ECM result in fibrosis. Left atrial biopsy samples in patients with AF undergoing cardiac surgery have higher levels of collagen compared controls without AF with increased collagen crosslinking. In addition, fibroblast and lymphomononuclear cells proliferate and infiltrate atrial tissue. Fibroblasts differentiate into activated myofibroblasts and secrete paracrine factors and extracellular membrane proteins. This has been shown to cause cardiomyocyte de-differentiation into embryonic precursor cells. Cardiomyocyte structure and function across the atrial myocardium become heterogeneous, with varying levels of hypertrophy, necrosis, apoptosis and proliferation. This heterogeneity, in animal models, provides a substrate for AF initiation and perpetuation by interrupting cellular conduction and signalling.

Recent evidence suggests that epicardial adipose tissue may play a major role in cardiac inflammation and fibrosis potentially explaining why obesity is a risk factor for AF (although it is important to note that epicardial fat does not necessarily correlate with BMI). Definitions of epicardial adipose tissue vary (many studies include fat in the pericardial space), but the largest such study in humans – involving the Framingham cohort – found a strong relationship
between pericardial fat (measured by CT) and AF.\textsuperscript{18} Other studies have associated pericardial/epicardial fat with recurrent AF after ablation.\textsuperscript{19, 20} Adipose tissue is known to stimulate the production of proinflammatory TNF-\(\alpha\), IL-6, TGF-\(\beta\) and MMPs. Thus, a paracrine effect on atrial myocardium, resulting in inflammation and fibrosis, has been postulated as a mechanism for the generation of AF substrate, as well as the direct effects of adipose infiltration into the myocardium.\textsuperscript{21} Clinical assessment of these processes could help determine left atrial health and may serve as useful prognostic markers.

**Fibrosis as a therapeutic target – is there any benefit?**

Reducing left atrial fibrosis could have important clinical implications. A number of animal studies have shown the adverse effects of left atrial fibrosis. Li et al showed that angiotensin II signalling and atrial fibrosis were increased by ventricular tachypacing but this could be attenuated with enalapril.\textsuperscript{22} In a rabbit model of heart failure, inhibition of angiotensin II with pioglitazone and candesartan reduced atrial fibrosis, conduction delay and levels of TGF-\(\beta\)1 and TNF-\(\alpha\).\textsuperscript{23} Clinical studies have shown similar promise. The TRACE study reported a reduction in AF incidence in patients with LV impairment treated with trandalopril after myocardial infarction – reduction in angiotensin signalling perhaps leading to a reduction in atrial fibrosis.\textsuperscript{24} Furthermore, Vermes et al. showed that enalapril could prevent AF in heart failure patients.\textsuperscript{25} Treatment with irbesartan in addition to amiodarone after electrical cardioversion appears to prevent AF recurrence in the absence of heart failure.\textsuperscript{26} A potential anti-fibrotic role of ACE inhibition was supported in a study by Boldt et al. who showed a reduction collagen deposition in ACEI -
treated patients. However, in meta analysis and in studies which used AF as a pre-determined endpoint, evidence was less convincing - particularly in patients without heart failure - that inhibition of the renin – angiotensin system prevents AF. The clinical utility of ACE inhibition for AF remains debatable.

Statins may exert anti-inflammatory, anti-oxidant and endothelium – stabilising effects that could reduce formation of fibrotic tissue. In animal histological experiments, statins have shown beneficial effects on atrial remodelling, and a reduction in fibrosis, likely as a result of reduced inflammation. Subsequent trials in humans have been mixed, and the largest meta-analysis revealed no benefit of statins for primary or secondary prevention of AF. Similarly, corticosteroids, which are anti-inflammatory, have not shown clinical benefit.

**Predicting the success of treatment with circulating markers of fibrosis**

There is a dearth of data on the role of circulating markers of fibrosis and maintenance of sinus rhythm in patients with AF (table 1). Neither atrial nor ventricular fibrosis is specific to AF and a specific of cardiac fibrosis has been identified. Two studies have attempted to correlate intracardiac marker levels with peripheral levels. In these studies, blood was obtained via catheterization of the left atrium and coronary sinus, but there were no
differences in circulating marker were found. Clinical studies have understandably excluded a large number of “real world” patients with AF because of confounding comorbidities. Positive associations between circulating fibrotic markers and rhythm outcome have only been found in small trials and subgroups of larger ones. As a result, odds or hazard ratio confidence interval lower limits are often close to 1. So far it seems that only markers of collagen types I and III turnover, e.g. PIIINP and CITP have shown promise. Conclusions about such biomarkers should be drawn very cautiously, however. As can be seen in the studies represented in table 1, the patient populations are heterogenous, particularly in terms of the character of AF. Duration, number of episodes, and previous treatment of AF are either poorly reported or not at all. The conventional AF classification (paroxysmal, persistent, permanent etc.) may not be sufficiently discriminative to describe the spectrum of pathology in AF patients – thus allowing for significant heterogeneity across study populations. It is perhaps unsurprising, therefore, that results frequently conflict.

**Conduction in the fibrotic atrium**

The mechanisms by which fibrosis may cause arrhythmia are not yet fully described, and are thought to be diverse (Figure 2).

**Extracellular changes**

The architecture of fibrotic myocardial tissue is heterogeneous, and this has a variable impact on intercellular conduction. In particular ‘interstitial’ and ‘patchy’ fibrosis, characterised by the presence of long strands of collagenous
material forming insulating septa between bundles of cardiomyocytes (perimysial fibrosis) as well as increasing the physical distance between cells (endomysial fibrosis).\textsuperscript{36} Such extracellular structural alterations appear to be progressive and associated with the duration of AF.\textsuperscript{37} In a persistent AF goat model, this pattern has been shown to increase electrical anisotropy.\textsuperscript{38} Furthermore, optical mapping of human left atrial appendages in patients with AF have corroborates the findings of slower conduction, and structural and functional block, which are arrhythmogenic.\textsuperscript{39, 40}

**Cellular changes**

Cardiomyocytes change structurally and physiologically, in effect entering into a hibernating state and displaying features usually associated with their embryological state.\textsuperscript{41} As a result, contractility and excitability are reduced.\textsuperscript{16} In addition, fibroblasts proliferate and differentiate into myofibroblasts.\textsuperscript{42}

This is important as fibroblasts have modulating effects on conduction in cardiomyocytes, e.g. in response to mechanical stretch.\textsuperscript{43} Studies in rats have demonstrated how myofibroblasts can cause slow conduction.\textsuperscript{44} The resting membrane potential in fibroblasts is less depolarised than cardiomyocytes, allowing them to act as a current ‘sink’, increasing the cardiomyocyte refractory period.\textsuperscript{45} Depolarization of fibroblasts appears to stimulate them to increase production of ECM.\textsuperscript{45}
The presence of these abnormal cell types is associated with abnormal conduction. For example, conduction velocity appears to be decreased by mechanical coupling and paracrine mediation between cardiomyocytes and fibroblasts. TGF-B1, angiotensin II, VEGF, TNF-A, endothelin-1 have been postulated as paracrine mediators.

Normal functional communication between myocardial cells is achieved, in part, via gap junctions, expressed by fibroblasts, myofibroblasts, and cardiomyocytes. Gap junctions are identified experimentally by labelling of their structural proteins, connexins (Cx). In animals, lower levels of Cx 40 seen in AF are thought be a marker of abnormal gap junction function. In human AF, connexin expression becomes heterogenous and is increased along lateral borders of cardiomyocytes. This finding is supported by electron microscopy, and implies abnormal intercellular communication at sites outwith the intercalated disc.

Fibrosis and AF are associated with disordered electrotonic coupling, e.g. alteration of intracellular calcium concentration in the myofibroblast. Such arrhythmogenic ion alterations have been well documented in AF. Phenomena such as automaticity and ectopy may occur, at least in part, due to this fibrosis - induced disordered electrotonic coupling, as demonstrated in computational modelling studies.

How, then, do these microscopic mechanisms translate to macroscopic electrical changes in the atrium? In a small study (n=6) of bi-atrial mapping in surgical
patients with AF, lines of conduction block were noted in the right atrium, around which multiple large wavefronts propagated. In the left atrium, multiple, high frequency, repetitive activity was documented - lending weight to the hypothesis that focal triggers and an arrhythmogenic substrate exist in humans. In a sheep heart failure model, fibrosis coincided with enhanced endocardial breakthrough in the posterior LA, with intra-mural re-entry allowing maintenance of AF. An earlier human study supported the heterogenous complexity of wavefronts. Finally, there is significant longitudinal dissociation between muscle bundles (with higher levels of dissociation in persistent AF cf. acute AF). This results in transient, dynamic alterations in wave boundaries, but with fibrillation waves that correspond spatially to muscle bundle structure. The predominant feature of persistent AF in this study was longitudinal dissociation of conduction with lines of block running in parallel with the muscle fibres. More chaotic fusion and collision of wavefronts were seen in acute (induced) AF, suggesting a more organised AF substrate in long-standing AF.

The identification of tissue displaying these properties, referred to clinically as electrophysiological substrate, has been attractive to clinicians for some time, hoping that targeting, or isolating, such areas during ablation procedures may increase procedural success. A number of clinical tools have been suggested as a means to identify such tissue. e.g. ablation of complex fractionated electrograms, however, recent randomised evidence suggests clinical outcomes may not be improved by such existing approaches in persistent AF.
Identification of fibrosis and targeting of ablation with electro-anatomical mapping

The presence of areas of low voltage within the left atrium is independently associated with recurrence of atrial arrhythmia after percutaneous ablation, and regional structural remodelling (as seen in fibrotic atria) has been associated spatially with such low voltage areas. Pulmonary vein isolation remains the mainstay of AF ablation, but the identification and ablation or isolation of low-voltage areas is a possible therapeutic strategy with encouraging early indications in both paroxysmal and non-paroxysmal AF.

Electrophysiological AF substrate is thought, in some instances, to be manifest by complex fractionated electrocardiograms (CFAE), although the precise aetiology of CFAE is debated, and they are not unique to fibrotic tissue. However, attempts have been made to relate CFAEs to atrial fibrosis in humans, after evidence that they relate to fibrosis and disordered connexin expression in animals. Also, computational modelling suggests that fibroblasts may contribute to the presence of CFAE. In the study in humans by Jadidi et al. however, CFAE did not relate to areas of fibrosis identified by MRI. Lower voltage did relate to these fibrotic areas. In the past, CFAE ablation has been a widely-used strategy, but it appears from these results that CFAE does not equate sufficiently with substrate, perhaps explaining the limited overall success of this approach. Operators must now consider whether targeted CFAE ablation can be justified at all, particularly in the light of the STAR-AF II trial.
which showed no benefit over pulmonary vein isolation alone in persistent AF ablation.\textsuperscript{61}

Focal impulse and rotor modulation (FIRM) is being explored as a novel method to isolate or ablate AF substrate and / or triggers.\textsuperscript{71} The phenomena identified by FIRM (focal impulses and rotors) have been demonstrated in experimental models of AF, although evidence for their role in initiating and maintaining human AF is lacking.\textsuperscript{72} No clear link with fibrosis has been identified. Recent long-term outcome data has been disappointing (in contrast to earlier studies), and randomized data is called for.\textsuperscript{73}

It is therefore apparent that electrophysiological mapping has its limitations. Although identification of low voltage areas has some promise, voltage cut-offs for the identification of atrial fibrosis are not established, although a classification system has been suggested.\textsuperscript{74} Accurate assessment of myocardial voltage requires adequate contact between the mapping catheter and the myocardium, but high-density mapping catheters with such an ability are unavailable. Similarly, the orientation of the catheter, the underlying rhythm, the electrode size and the distance between poles all have an impact on accurate voltage assessment. The inherent problem of spatial error and drift during a long AF case poses a challenge to the idea of targeting areas of fibrosis precisely. EP mapping is not suitable to aid the selection of ablation patients.
Pre-procedural imaging of fibrosis

Echocardiography remains the initial method of screening for underlying heart disease that may imply lower chances of success – such as left atrial dilatation, valvular heart disease, or left ventricular systolic impairment. Magnetic resonance imaging (MRI) and computed tomography (CT), have further advantages including more accurate analysis of cardiac chamber volume and function. Left atrial fibrosis can be detected by MRI (T1 mapping and delayed gadolinium enhancement) or echocardiographic integrated backscatter. The latter is not routinely used, but is widely available. It has been associated with an increased risk of arrhythmia recurrence after ablation. The technique is semi-quantitative, and is subject to the limitations of any echocardiographic technique, principally inter-operator variation and the variability of image quality between patients. It also lacks the potential to provide information regarding the spatial location of fibrotic areas within the atrium.

Late gadolinium enhancement (LGE) MRI, on the other hand, can be used to quantify overall atrial burden of fibrosis and display it onto a 3-dimensional reconstruction. Gadolinium is taken up by cardiac tissue but remains within fibrotic tissue for longer than normal tissue. The technique is heavily dependent on accurate left atrial segmentation and takes time. The principal disadvantage of MRI, at least at present, hinges around limitations in spatial resolution; the smallest resolvable dimension may be similar to the thickness of the atrial wall itself, making both qualitative and quantitative assessment of gadolinium uptake
challenging. Also MRI is less readily available than echocardiography.

Nevertheless, a number of studies, most notably the DECAAF study by Marrouche et al., have shown significant correlation between fibrosis and ablation outcome \[77-79\]. The group have proposed a classification of LA fibrosis from stages I (<10% of the LA wall) to IV (>30%), with recurrence rates of 15% and 51%, respectively.

The use of LGE-MRI to guide targeted ablation of discrete areas of fibrosis has not yet been studied in depth, although Oakes et al. showed a quantitative relationship between gadolinium enhancement and low voltage areas on EP mapping. \[80\] Improvement in MRI spatial resolution and the combination of MRI data with EP data may aid targeted ablation or isolation of AF substrate.

**Conclusion**

Fibrosis is important in the pathophysiology of AF. A number of methods of assessing the extent of fibrosis are available, but have not been validated for clinical use. How this data relates to successful restoration of sinus rhythm remains unclear. A clinical score to predict outcome based on data from multiple sources (e.g. MRI and biomarkers) may be what is needed to help guide clinicians as to which patients will maintain sinus rhythm in the long term, however, as we have discussed in this review, there are significant conflicts in existing data, such that any such scoring system seems a distant prospect. Further fundamental research is required, perhaps even redressing the manner in which AF is conventionally classified, in order to provide a stable platform for future therapeutic directions.
REFERENCES


[54] Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007;87:425-56.


Table 1. Studies of relationship between circulating biomarkers of fibrosis and outcome of cardioversion and percutaneous ablation.

<table>
<thead>
<tr>
<th>Author</th>
<th>Ref</th>
<th>Sample</th>
<th>Fibrosis marker(s)</th>
<th>Study pop.</th>
<th>Controls</th>
<th>Follow up (months)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cardioversion</td>
</tr>
<tr>
<td>Kim</td>
<td>81</td>
<td>Plasma</td>
<td>TGF-β, MMP 9</td>
<td>81</td>
<td>-</td>
<td>13</td>
<td>Multivariate analysis. Length of follow up widely variable. TGF-β predicted DCCV failure but not recurrence of AF after successful DCCV.</td>
</tr>
<tr>
<td>Kato</td>
<td>82</td>
<td>Serum / plasma</td>
<td>MMP 2, TIMP 2, MMP 1, 9</td>
<td>102</td>
<td>-</td>
<td>28</td>
<td>Pharmacological cardioversion, DCCV if unsuccessful.</td>
</tr>
<tr>
<td>Lombardi</td>
<td>83</td>
<td>DNA (PCR)</td>
<td>MMP 1, 3</td>
<td>74</td>
<td>-</td>
<td>3 weeks</td>
<td>Analysis of gene polymorphism. Short follow up.</td>
</tr>
<tr>
<td>Kawamura</td>
<td>84</td>
<td>Serum</td>
<td>PIIINP</td>
<td>142</td>
<td>-</td>
<td>24</td>
<td>Pharmacological cardioversion, DCCV if unsuccessful. Excluded ACEI/ARB and BB. Short AF duration.</td>
</tr>
<tr>
<td>Mukherjee</td>
<td>85</td>
<td>Plasma</td>
<td>MMP 3, 9, TIMP 4</td>
<td>82</td>
<td>-</td>
<td>3</td>
<td>Open to type 1 error due to multiple markers. Short follow up.</td>
</tr>
<tr>
<td>Kallergis</td>
<td>86</td>
<td>Serum</td>
<td>CITP, CICP</td>
<td>164</td>
<td>Normal</td>
<td>2</td>
<td>Information on comorbidities not published. Short follow up. Population not representative - multiple exclusion criteria</td>
</tr>
<tr>
<td>Kim</td>
<td>87</td>
<td>Serum</td>
<td>TGF-β, MMP 1, 2, 9</td>
<td>242 (mixed PAF and PoAF)</td>
<td>-</td>
<td>22</td>
<td>Aimed to show relationship between TGF-β1, TIMP 1, and</td>
</tr>
</tbody>
</table>

Percutaneous ablation
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample Type</th>
<th>Biomarkers</th>
<th>Sample Size</th>
<th>Follow-Up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Okamura</td>
<td>Serum/plasma</td>
<td>MMP 2, CITP, TIMP 2, TIMP 1</td>
<td>25 samples from LA or mid CS</td>
<td>-</td>
<td>AADs stopped at 3 months. MMP 2 predicted recurrence irrespective of PAF/non-PAF. No diff. between LA/CS and peripheral levels. Small sample size.</td>
</tr>
<tr>
<td>Richter</td>
<td>Serum/plasma</td>
<td>PIIINP, but only MMP 9, TGF-β1 over course of follow up</td>
<td>30</td>
<td>-</td>
<td>Small sample size. Not aimed at determining predictive value of baseline levels, but changes in levels over post-ablation time course.</td>
</tr>
<tr>
<td>Wu</td>
<td>Plasma</td>
<td>TGF-β1 in non-PAF</td>
<td>-</td>
<td>200 (mixed PAF/non-PAF)</td>
<td>TGF-β1 predicted recurrence in the 46 non-PAF patients; relatively small sample size for this positive association compared to overall number. 95% CI for odds ratio 1.01-1.22.</td>
</tr>
<tr>
<td>Kimura</td>
<td>Serum</td>
<td>MMP 2, CITP, PINP, TIMP 2, TIMP 1, TGF-β</td>
<td>-</td>
<td>44</td>
<td>Multiple markers, open to type 1 error. Small sample size.</td>
</tr>
<tr>
<td>Sasaki</td>
<td>Serum</td>
<td>MMP 2, TIMP 2, TGF-β1</td>
<td>-</td>
<td>60</td>
<td>AADs stopped at 2 months. Aimed at post-ablation changes in levels.</td>
</tr>
<tr>
<td>Song</td>
<td>Serum</td>
<td>CTGF in non-PAF</td>
<td>-</td>
<td>400 (mixed PAF/non-PAF)</td>
<td>AADs stopped at 3 months. Of 400 patients, 92 were non-</td>
</tr>
<tr>
<td>Study</td>
<td>Patients</td>
<td>Plasma Samples</td>
<td>Gal-3</td>
<td>TGF-β1 (in multivariate analysis)</td>
<td>AADs Stopped</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
<td>----------------</td>
<td>-------</td>
<td>----------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Kornej</td>
<td>10</td>
<td>-</td>
<td>105</td>
<td>(mixed PAF/PeAF)</td>
<td>14</td>
</tr>
<tr>
<td>Canpolat</td>
<td>Plasma</td>
<td>-</td>
<td>41</td>
<td>(PAF)</td>
<td>18</td>
</tr>
<tr>
<td>Wu</td>
<td>Plasma</td>
<td>Gal-3</td>
<td>50</td>
<td>(PeAF, lone)</td>
<td>46</td>
</tr>
</tbody>
</table>

For abbreviations, see main list.
Figures

Figure 1 title – Biomarkers in fibrosis.

Figure 1 legend – green boxes indicate substances measurable in the circulation.

Figure 2 title – Conduction abnormalities in atrial fibrosis